Prabodh Mehta, MD
Cardiovascular Disease · Elizabethtown, KYNPI 1982606604
Payments from drug & device makers
Across 504 payments — averaging $403.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$100K
- Esperion Therapeutics, Inc.$89K
- AstraZeneca$11K
- Terumo Medical Corporation$700
- Abbott$700
- Novartis$401
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$90,59468%
- Travel & lodging$36,69928%
- Food & beverage$5,3504%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 115 | $99,976 |
| Esperion Therapeutics, Inc. | 152 | $88,616 |
| AstraZeneca | 33 | $10,715 |
| Terumo Medical Corporation | 8 | $700 |
| Abbott | 31 | $700 |
| Novartis | 28 | $401 |
| Amgen | 25 | $359 |
| Johnson & Johnson | 29 | $319 |
| Pfizer | 9 | $165 |
| Boston Scientific | 2 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $139 |
| Amarin Pharma, Inc. | 8 | $126 |
| Chiesi USA, Inc. | 9 | $125 |
| Cardiovascular Systems Inc. | 4 | $103 |
| Alnylam Pharmaceuticals Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Lundbeck LLC | 4 | $69 |
| Astellas Pharma US Inc | 2 | $67 |
| Lexicon Pharmaceuticals, Inc. | 3 | $51 |
| Boehringer Ingelheim | 3 | $38 |
| Acist Medical Systems, Inc. | 2 | $32 |
| Novo Nordisk | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $21 |
| Inari Medical, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Verge Medical, Inc. | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
| Elutia, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$185,269
- NEXLIZET$17,914
- NEXLETOL$17,914
- FARXIGA$10,150
- Optitorque$574
- Heartrail$574
- TR Band$574
- Glidesheath$574
- Xience V coronary stent system$302
- GENERAL VASCULAR INTERVENTION$143
- BRILINTA$125
How this compares
$203,263 in reported general payments places this provider in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 16 | $703,640 |
| EntrestoSacubitril/Valsartan | 167 | $186,822 |
| FarxigaDapagliflozin Propanediol | 107 | $68,566 |
| VerquvoVericiguat | 50 | $49,482 |
| EliquisApixaban | 38 | $28,816 |
| JardianceEmpagliflozin | 30 | $28,316 |
| InpefaSotagliflozin | 26 | $16,455 |
| DapagliflozinDapagliflozin Propanediol | 19 | $8,520 |
| XareltoRivaroxaban | 12 | $7,721 |
| BrilintaTicagrelor | 12 | $5,209 |
| Spironolactone | 267 | $1,796 |
| Metoprolol Succinate | 108 | $1,672 |
| Carvedilol | 178 | $1,240 |
| Bumetanide | 24 | $1,132 |
| Digoxin | 31 | $602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $165 | $732,45554 claims |
| NovartisEntresto | $401 | $186,822167 claims |
| AstraZenecaFarxiga, Brilinta | $10,715 | $73,775119 claims |
| MerckVerquvo | $99,976 | $49,48250 claims |
| Boehringer IngelheimJardiance | $38 | $28,31630 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $51 | $16,45526 claims |
| Johnson & JohnsonXarelto | $319 | $7,72112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Elizabethtown
- Kishor VoraOwensboro$4.5M
- Dinesh KalraLouisville$739K
- Amir PirachaLouisville$590K
- Rohan SamsonLouisville$527K
- Shahab GhafghaziLouisville$404K
- William SkinnerLexington$346K
- Vipul PanchalLouisville$301K
- John KotterLexington$241K
- John HarrisLouisville$226K
- Suresh SharmaLexington$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.